LLYvsPFE
Eli Lilly and CovsPfizer Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.
Eli Lilly and Co
$883.96
-15.15%
Pfizer Inc
$27
+2.16%
60-day price, rebased to 100
Round-by-round
Valuation upside
-69.50% vs -19.10% to DCF fair value
Balance-sheet strength
Altman Z 8.14 vs 2.15
Fundamental quality
Piotroski 8.00 vs 6.00 (of 9)
Growth + margins
Rule-of-40 53.90 vs 12.90
60-day momentum
-15.34% vs +3.45% price return
Market-cap liquidity
$884.0B vs $155.1B
Verdict
Across6categories,LLYtakes the edge with4wins to2. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.
Backtest a strategy onLLYorPFE
Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.